Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a specific reporting date of February 14, 2022. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on the London Stock Exchange (XLON) on February 10, 2022.
| Transaction Type | Individual | Volume | Price (GBP) | Instrument |
|---|---|---|---|---|
| Sale | Ms S Jackson (SVP) | 1,226 | 16.3267 | Ordinary Shares |
| Purchase | Ms S Jackson (SVP) | 1,218 | 16.3210 | Ordinary Shares |
| Sale | Mr D Jackson (PCA) | 1,226 | 16.3287 | Ordinary Shares |
| Purchase | Mr D Jackson (PCA) | 1,219 | 16.3133 | Ordinary Shares |
Material Changes
The filing does not report material changes to the company's financial position or operations. The transactions described are administrative in nature, executed to facilitate transfers into Individual Savings Accounts (ISAs). There is no comparative period data provided within this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The document is a statutory disclosure of insider trading activity required under the Securities Exchange Act of 1934.
Investor Verification Points
- Verify the total net change in share ownership for Ms S Jackson and Mr D Jackson following the ISA transfers.
- Confirm the transaction prices align with the market price of GSK ordinary shares on February 10, 2022.
- Note that this filing does not reflect the company's broader financial health or operational results for the period.